Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole

Ther Drug Monit. 2012 Dec;34(6):739-41. doi: 10.1097/FTD.0b013e318271b6e6.

Abstract

A 17-year-old adolescent with acute nephrotoxicity had CYP3A4-5, CYP2C19, and ABCB1 genotyping performed to understand a suspected drug interaction between tacrolimus and omeprazole. The determinant role of individual pharmacogenetic profile in the occurrence of tacrolimus nephrotoxicity is presented and discussed.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • Adolescent
  • Anti-Ulcer Agents / adverse effects*
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Biotransformation / drug effects
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP3A / genetics
  • Cytochrome P-450 CYP3A / metabolism
  • Drug Interactions
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / blood
  • Immunosuppressive Agents / pharmacokinetics*
  • Kidney Transplantation / adverse effects
  • Omeprazole / adverse effects*
  • Tacrolimus / adverse effects
  • Tacrolimus / blood
  • Tacrolimus / pharmacokinetics*
  • Treatment Outcome

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Anti-Ulcer Agents
  • Immunosuppressive Agents
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Omeprazole
  • Tacrolimus